$SKB BIO-B(06990)$ 在创新药赛道，科伦博泰

21
1
Favorite

$SKB BIO-B(06990)$ 在创新药赛道，科伦博泰凭借强大的研发实力脱颖而出，持续加大在生物药、小分子创新药等领域的投入，多项管线产品进入关键临床阶段，如靶向肿瘤的创新药物，展现出良好的疗效与市场潜力。公司还积极与国际药企开展合作，通过授权海外权益的方式，快速实现创新成果的价值转化，2024年与默沙东的合作交易，更是彰显其研发实力获得国际认可。在仿制药板块，规模效应与成本优势明显，为公司提供稳定现金流。从估值来看，相较于同行业创新药企，其股价仍具备较大的成长空间，是极具潜力的投资标的。

06990

06-06 14:23

HKSKB BIO-B

Side	Price \| Filled	Realized P&L
Buy Open	333.00 200	-- Closed

SKB BIO-B

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

Top
Latest

DeltaDrift
·06-06
仿制药业务提供稳定现金流，支持创新投入，双轮驱动模式较为稳健。若后续关键临床数据顺利披露，叠加估值修复预期，确实值得中长期关注。感谢分享。
Reply
Like
Report

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":443057416704640,"tweetId":"443057416704640","gmtCreate":1749191067748,"gmtModify":1749433433983,"author":{"id":4185525996531482,"idStr":"4185525996531482","authorId":4185525996531482,"authorIdStr":"4185525996531482","name":"一追再追","avatar":"https://community-static.tradeup.com/news/c8afd30911053e792d09d1f067fb7588","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":13,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.07","individualDisplayEnabled":0},"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.12.25","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}}],"fanSize":449,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":267,"starInvestorOrderShareNum":1199,"userFollowInvestorFlag":false,"orderNotificationFlag":false,"ror":25.8,"showRor":true,"investmentPhilosophy":"股票本無害，多炒亦正常。本來無挾倉，何以輸爆廠？","winRationPercentage":86.576355,"tradeVolumeEst":0},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/06990\">$SKB BIO-B(06990)$&nbsp;</a>在创新药赛道，科伦博泰凭借强大的研发实力脱颖而出，持续加大在生物药、小分子创新药等领域的投入，多项管线产品进入关键临床阶段，如靶向肿瘤的创新药物，展现出良好的疗效与市场潜力。公司还积极与国际药企开展合作，通过授权海外权益的方式，快速实现创新成果的价值转化，2024年与默沙东的合作交易，更是彰显其研发实力获得国际认可。在仿制药板块，规模效应与成本优势明显，为公司提供稳定现金流。从估值来看，相较于同行业创新药企，其股价仍具备较大的成长空间，是极具潜力的投资标的。</body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/06990\">$SKB BIO-B(06990)$&nbsp;</a>在创新药赛道，科伦博泰凭借强大的研发实力脱颖而出，持续加大在生物药、小分子创新药等领域的投入，多项管线产品进入关键临床阶段，如靶向肿瘤的创新药物，展现出良好的疗效与市场潜力。公司还积极与国际药企开展合作，通过授权海外权益的方式，快速实现创新成果的价值转化，2024年与默沙东的合作交易，更是彰显其研发实力获得国际认可。在仿制药板块，规模效应与成本优势明显，为公司提供稳定现金流。从估值来看，相较于同行业创新药企，其股价仍具备较大的成长空间，是极具潜力的投资标的。</body></html>","text":"$SKB BIO-B(06990)$ 在创新药赛道，科伦博泰凭借强大的研发实力脱颖而出，持续加大在生物药、小分子创新药等领域的投入，多项管线产品进入关键临床阶段，如靶向肿瘤的创新药物，展现出良好的疗效与市场潜力。公司还积极与国际药企开展合作，通过授权海外权益的方式，快速实现创新成果的价值转化，2024年与默沙东的合作交易，更是彰显其研发实力获得国际认可。在仿制药板块，规模效应与成本优势明显，为公司提供稳定现金流。从估值来看，相较于同行业创新药企，其股价仍具备较大的成长空间，是极具潜力的投资标的。","highlighted":1,"essential":1,"paper":1,"likeSize":21,"commentSize":1,"repostSize":1,"favoriteSize":0,"link":"https://ttm.financial/post/443057416704640","repostId":0,"isVote":1,"tweetType":1,"viewCount":1248,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["06990"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":true,"orderData":{"uuid":"4185525996531482","orderId":"39359845809277952","kind":"TRADE","symbol":"06990","secType":"STK","symbolHtmlTag":"<a href=\"https://ttm.financial/S/06990\">$SKB BIO-B(06990)$&nbsp;</a>","symbolHtmlTagHref":"https://ttm.financial/S/06990","symbolName":"SKB BIO-B","market":"HK","action":"BUY","currency":"HKD","symbolLogo":"","showFilledQuantity":true,"nameCN":"SKB BIO-B","orderType":"LMT","filledQuantityFinal":200,"avgFillPrice":333,"createTime":1749190992,"filledQuantity":"200","filledQuantityScale":"0","openFlag":true,"side":"DEBIT","contractMajorDescription":"SKB BIO-B","contractExtraDescription":"06990","legs":[],"completedFlag":true,"orderPnl":{"openRealizedPnlPercent":0.0224},"quickOrderFlag":false},"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["订单分享帖"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":true,"length":439,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":443195502641688,"commentId":"443195502641688","gmtCreate":1749204332846,"gmtModify":1749204338575,"authorId":10000000000011028,"author":{"id":10000000000011028,"idStr":"10000000000011028","authorId":10000000000011028,"name":"DeltaDrift","avatar":"https://community-static.tradeup.com/news/11d675a610354289230d3a2f6c6e4c88","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":443057416704640,"objectIdStr":"443057416704640","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"仿制药业务提供稳定现金流，支持创新投入，双轮驱动模式较为稳健。若后续关键临床数据顺利披露，叠加估值修复预期，确实值得中长期关注。感谢分享。","text":"仿制药业务提供稳定现金流，支持创新投入，双轮驱动模式较为稳健。若后续关键临床数据顺利披露，叠加估值修复预期，确实值得中长期关注。感谢分享。","html":"仿制药业务提供稳定现金流，支持创新投入，双轮驱动模式较为稳健。若后续关键临床数据顺利披露，叠加估值修复预期，确实值得中长期关注。感谢分享。","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"hasMoreComment":true,"orderType":2}